I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
C series
—
(Competition - Concentrations - Pharmaceutical industry market - Genetic sequencing systems - Acquisition by Illumina of sole control over Grail - Decision imposing interim measures pursuant to Article 8(5)(c) of Regulation (EC) No 139/2004 - Withdrawal of the contested act - Disappearance of the subject matter of the action - No need to adjudicate)
(C/2025/1884)
Language of the case: English
Applicant: Illumina, Inc. (Wilmington, Delaware, United States) (represented by: D. Beard, Barrister-at-Law, and by F. González Díaz, M. Siragusa and T. Spolidoro, lawyers)
Defendant: European Commission (represented by: G. Conte, B. Ernst and P. Berghe, acting as Agents)
By its action based on Article 263 TFEU, the applicant seeks the annulment of Commission Decision C(2022) 7889 final of 28 October 2022 to adopt interim measures (Case M.10938 – Illumina/Grail) pursuant to Article 8(5)(c) of Council Regulation (EC) No 139/2004 of 20 January 2004 on the control of concentrations between undertakings (OJ 2004 L 24, p. 1).
1.There is no longer any need to adjudicate on the action.
2.There is no longer any need to adjudicate on the application to intervene lodged by Grail LLC.
3.The European Commission shall bear its own costs and shall pay those incurred by Illumina, Inc.
4.Grail LLC shall bear its own costs.
—
(1)
OJ C 63, 20.2.2023.
—
ELI: http://data.europa.eu/eli/C/2025/1884/oj
ISSN 1977-091X (electronic edition)
—